WO2002085246A2 - Fabrication of a polymeric prosthetic implant - Google Patents

Fabrication of a polymeric prosthetic implant Download PDF

Info

Publication number
WO2002085246A2
WO2002085246A2 PCT/US2002/012283 US0212283W WO02085246A2 WO 2002085246 A2 WO2002085246 A2 WO 2002085246A2 US 0212283 W US0212283 W US 0212283W WO 02085246 A2 WO02085246 A2 WO 02085246A2
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
chains
construct
prosthetic implant
primary
Prior art date
Application number
PCT/US2002/012283
Other languages
French (fr)
Other versions
WO2002085246A3 (en
Inventor
David Dean
Malcolm Cooke
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Priority to AU2002305201A priority Critical patent/AU2002305201A1/en
Publication of WO2002085246A2 publication Critical patent/WO2002085246A2/en
Publication of WO2002085246A3 publication Critical patent/WO2002085246A3/en

Links

Classifications

    • GPHYSICS
    • G05CONTROLLING; REGULATING
    • G05BCONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B19/00Programme-control systems
    • G05B19/02Programme-control systems electric
    • G05B19/18Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form
    • G05B19/4097Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form characterised by using design data to control NC machines, e.g. CAD/CAM
    • G05B19/4099Surface or curve machining, making 3D objects, e.g. desktop manufacturing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2/30942Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56Porous materials, e.g. foams or sponges
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10Processes of additive manufacturing
    • B29C64/106Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
    • B29C64/124Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
    • B29C64/129Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask
    • B29C64/135Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/40Structures for supporting 3D objects during manufacture and intended to be sacrificed after completion thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00Processes of additive manufacturing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y50/00Data acquisition or data processing for additive manufacturing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00Materials specially adapted for additive manufacturing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00Products made by additive manufacturing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/56Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A61B17/58Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
    • A61B17/68Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
    • A61B17/84Fasteners therefor or fasteners being internal fixation devices
    • A61B17/86Pins or screws or threaded wires; nuts therefor
    • A61B17/866Material or manufacture
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/56Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A61B2017/568Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor produced with shape and dimensions specific for an individual patient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30062(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30108Shapes
    • A61F2002/30199Three-dimensional shapes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2/30942Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
    • A61F2002/30948Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using computerized tomography, i.e. CT scans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2/30942Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
    • A61F2002/30952Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using CAD-CAM techniques or NC-techniques
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2/30942Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
    • A61F2002/30962Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using stereolithography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063Three-dimensional shapes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29KINDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037Other properties
    • B29K2995/0072Roughness, e.g. anti-slip
    • B29K2995/0073Roughness, e.g. anti-slip smooth
    • GPHYSICS
    • G05CONTROLLING; REGULATING
    • G05BCONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B2219/00Program-control systems
    • G05B2219/30Nc systems
    • G05B2219/45Nc applications
    • G05B2219/45172Prosthesis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10Methods of surface bonding and/or assembly therefor
    • Y10T156/1089Methods of surface bonding and/or assembly therefor of discrete laminae to single face of additional lamina
    • Y10T156/109Embedding of laminae within face of additional laminae

Definitions

  • prosthetic devices made from these materials do not (a) revascularize or allow for tissue regeneration in the defect site, (b) integrate with the existing host bone, or (c) undergo subsequent remodeling in response to evolving mechanical (i.e., ambulatory loading or protection of internal organs) needs. This leads to problems with protective strength and aesthetics as the host bone remodels around the implanted prosthetic. The problems are magnified by the post-surgical need to protect the brain or other internal organs covered by prosthetic from infection and trauma during the healing process.
  • prosthetics that act as porous scaffold for attachment and proliferation of tissue progenitor (e.g., bone progenitor) cells. It has been proposed that such scaffolds be made from a biodegradeable polymer that slowly degrades away, eventually leaving a defect site that has been repaired by the cells which migrate into and attach to the scaffold. Prior to its degradation, the scaffold serves not only to provide a surface for attachment of the progenitor bone cells, but also to allow in nutrients and to support any biomechanical functions (ambulatory loading or protection).
  • tissue progenitor e.g., bone progenitor
  • Polymeric scaffolds have been fabricated by a chemical cross-linking process or, more recently, by photocrosslihking the liquid polymeric material in a transparent mold. Molds do not facilitate the formation of internal spaces such as pores. To overcome this deficiency, investigators have tried to stir salt crystals into the polymer and later leach it out with water. The salt crystal space is left as a pore, but the surface texture and arrangement of, pores is not homogenous and geometrically may not be conducive to cell attachment, proliferation, or maturation, as well as vascular ingrowth
  • biodegradable polymeric prosthetics for treating critical size bone defects. It is also desirable to have a method which provides a prosthetic that not only maintains its shape and protective strength during the healing process but also encourages bone ingrowth and incorporation of the prosthetic with the host bone. It is also desirable to have a method for fabricating a prosthetic which comprises a polymer that, when prosthetic implanted into a defect site, does not degrade into by-products that have serious adverse affects on the cells and tissues in contact with the prosthetic.
  • the present invention provides a method of fabricating a customized three- dimensional prosthetic implant for use in repairing a critical size tissue defect, particularly a critical size bone defect in a patient
  • critical size bone defect refers to a bone defect that the patient cannot heal without assistance.
  • customized refers to a prosthetic prosthetic implant whose size and shape dimensionally matches the bone defect site in the patient.
  • such prosthetic comprises a series of interconnecting pores that provide at least one channel, more preferably a network of interconnecting channels, leading from the exterior surface of the prosthetic implant to a predetermined location in the interior of the prosthetic implant.
  • the pores and channels are defined by surfaces which provide points of bone or vascular progenitor cells.
  • the present method comprise the following steps: providing a solution comprising chains of a photopolymerizable, bioerodable, liquid polymeric materials (referred to hereinafter as a " primary polymer") and a photoinitiator for promoting photocrosslinking of the primary polymer; providing a stereolithography instrument comprising a UV laser for activating the photoinitiator and photocrosslinking the primary polymer; providing a CAD image of the desired three-dimensional prosthetic prosthetic implant, wherein said CAD image is readable by the stereolithography instrument; depositing the solution in successive layers on a build platen in the stereolithography instrument; and photocrosslinking the primary polymer in each of the successive layers according to corresponding cross-sectional patterns derived from the CAD image.
  • the fabrication method may further comprise an earlier step of scanning a bone to be duplicated to provide data and converting the data into the three dimensional CAD image.
  • the primary polymer is a poly (propylene fumarate)(hereinafter "PPF")
  • the solution further comprises a solvent for reducing the viscosity of the PPF liquid.
  • the solution further comprises chains of one or more additional photopolymerizable polymers (referred to hereinafter as the "secondary polymer”) for preparing a composite prosthetic implant.
  • the present invention also provides an prosthetic implant prepared in accordance with the present method.
  • Such prosthetic implant comprises solid regions comprising the photocrosslinked primary polymer and has a network of interconnecting pores and channels leading from the exterior surface to an interior location in the prosthetic prosthetic implant.
  • the diameter of the pores and channels is from about 100 microns to about 1000 microns.
  • the prosthetic implant is a composite prosthetic prosthetic implant wherein a portion or all of the solid regions of the prosthetic prosthetic implant comprise a photcrosslinked primary polymer and a photocrosslinked secondary polymer, hi other embodiments, the prosthetic prosthetic implant is a composite prosthetic prosthetic implant wherein a first group of solid regions in the prosthetic implant comprise the photocrosslinked primary polymer and a second group of solid regions in the prosthetic implant comprise a photocrosslinked secondary polymer.
  • the prosthetic implant may also comprise bioactive molecules.
  • FIG. 1 Laser Curing Device (3D Systems 250/40 SLA): A CAD file is converted into slice data. A high resolution laser beam moves over a vat of resin. The resin is hardened to a prescribed depth of 0.1 mm (100 microns), one slice at a time. Elevator platfonn moves down 0.1 mm after each layer is polymerised. Adjacent layers polymerise to one another, held in registration by supports bound to the elevator (build) platen. (Image Copyright 3D Systems,
  • Figure 2 Pro/ENGINEER rendered CAD image of prototype PPF construct: The series of slots and projections test the inter-slice PPF registration. Overall dimensions are 50mm diameter x 4mm thick.
  • FIG. 3 Custom mini-build tank from above: It is located on the 3D System SLA 250 machine. Note that it takes advantage of the 3D systems elevator hardware but, at this time, not the wiper blade. A movie at http://neurosurgery.cwru.edu/imaging/public/index.html shows how it works.
  • Figure 4 Custom mini-build tank cross-sectional view: A CAD rendered image showing a section through the custom mini-build tank.
  • FIG. 5 SLA manufactured PPF/DEF prototype: This part was generated from CAD model data fed to an SLA 250/40.
  • the mottled (dots and lines) on undersurface indicate support structures that were previously attached to the mini-tank build platen.
  • the present invention provides a process for fabricating a customized, three- dimensional, bioresorbable, polymeric prosthetic implant, particularly a bone prosthetic implant, hi a highly preferred embodiment, the prosthetic implant has a porous network.
  • the method employs a sterolithography instrument, a solution comprising chains of one or more photocurable, bioerodable polymers and a photoinitiator, and a three-dimensional CAD image, h a highly preferred embodiment, the solution comprises poly (propylene) fumarate (PPF) and a solvent for controlling the viscosity of the solution.
  • the solution comprises chains of a second photocurable polymer or chains of a second photocurable polymer and a second photoinitiator.
  • the solution further comprises bioactive molecules that promote attachment, proliferation, and/or differentiation of vascular and/or bone progenitor cells.
  • the solution is placed in a container in the stereolithography instrument.
  • the container also holds a movable build platen for supporting each of the covalently bonded layers of the polymeric prosthetic implant that are formed when successive layers of the solution are exposed to UV light energy.
  • the UV light energy is imparted to selected portions of each layer of the solution to produce a pattern of cross-linked and non-cross-linked polymeric regions corresponding to a cross-sectional image of the three-dimensional CAD image.
  • the non-cross- linked polymeric resin in the prosthetic implant is washed away DEFINITIONS
  • bioerodable refers to a polymer whose solid form degrades by surface erosion or bioerosion rather than bulk degradation.
  • Two distinct types of degradation can occur with implanted solid polymers.
  • One type of degradation is bulk degradation, in which the polymer degrades in a fairly uniform manner throughout the matrix.
  • the prevailing mechanism of bulk degradation is hydrolysis of the hydrolytically unstable polymer backbone.
  • M n molecular weight
  • the second type of degradation is surface erosion, which is also called bioerosion.
  • Bioerosion occurs when the rate at which water penetrates the prosthetic implant is slower than the rate of the conversion of the polymer into water-soluble materials. Bioerosion results in a thinning of the prosthetic implant over time, though the prosthetic implant's bulk integrity is maintained.
  • PPF is a bioerodable polymer.
  • PLA, PGA, and PLGA may degrade in bulk and, therefore, for the purposes of the present invention, are not considered to be bioerodable polymers.
  • CAD computer aided design
  • CAD/CAM computer aided design
  • three-dimensional polymeric prosthetic implant is used herein to mean any polymeric prosthetic implant that substantially retains its intended function and shape when removed from an external support.
  • cross-sectional pattern is used herein to mean a representation of a cross-section of the prosthetic implant being built. Generally speaking, the cross-sectional pattern will be a complete vertical cross-section, because most prosthetic implants are contemplated to be produced one complete layer at a time, in a vertical, stepwise fashion.
  • the terms "photocrosshnk” and “photocure” as used herein are interchangeable and refer to a process that is initiated by exposure of a polymer to UV radiation in the presence of a photinitiator, and that results in the formation of chemical links between molecular chains of the polymer.
  • the bioresorbable polymers which are used to prepare the present prosthetic implants are uncrosslinked, or uncured, prior to exposure to activating UV radiation, hi accordance with the present methods, the final prosthetic implant comprises select and predetermined solid regions of a photocrosslinked or photocured polymer, preferably a photocrosslinked or photocured PPF polymer.
  • Successessive layer refers to the layer of solution that is sequentially deposited on the build platen or the previous photocrosslinked layer of the polymeric prosthetic implant during the stereolithographic procedure, hi accordance with the present invention, there is inter layer bonding between each of the photocrosslinked layers of the polymeric prosthetic implant.
  • Ultraviolet or UV radiation is radiation in the region of the electromagnetic spectrum including wave-lengths from 100 to 3900 angstroms.
  • step 1 of the present method a computer representation or three-dimensional "image" of the prosthetic implant to be formed, including its internal network of pores is generated using a CAD/CAM software system.
  • the software then preferably generates an STL file for use in a sterolithography instrument.
  • the STL file is converted into "slice" data corresponding to vertical cross-sectional patterns (X-Y slices of Z thickness) of the desired prosthetic implant, a process termed stereolithography (SLA).
  • SLA stereolithography
  • step 2 a layer of the solution is applied either to the work surface of the build platen or to a previous photocrosslinked polymeric layer. Thereafter, the layer is leveled to a desired thickness that corresponds to the thickness of the "slice” generated by the computer and the depth of polymerization of the particular laser/ initiator/ polymer combination used .
  • step 3 appropriate slice data from step 1 is fed to a selective photoexposure device, which in turn exposes the layer of solution deposited in step 2 to one or more scanning UV lasers according to the corresponding cross-sectional pattern derived from the three- dimensional CAD image.
  • Appropriate intensity and duration of the exposure is contemplated to be established experimentally. Nevertheless, it may be understood that suitable values for these parameters will vary as a function of numerous factors, including the nature of the photocurable polymers in the solution, the amount and activity of the photoinitiator, and the thickness and transparency of each layer to the radiation.
  • Such exposure is selected to provide a suitable, predetermined degree of cross-linking between the polymeric chains of the photocurable polymer, while still permitting adequate bonding between adjacent layers. Specific exposure parameters are given below, but in general it is contemplated that intensity will correspond to the wavelength at which the photoinitiator in the solution has maximum absorbance.
  • Variation of the laser intensity or traversal speed can be used to vary the cross-link density within a layer so that the physical properties of the solid polymeric regions can be varied from position to position within the prosthetic implant.
  • Cross-linking density can also be altered by varying the ratio of the photocurable polymer to solvent in the solution and by employing two or more photocurable polymers having different molecular weights and different numbers of cross-linking sites along the polymer chains.
  • step 4 the PPF oligomeric and polymeric chains in the solution are photocrosslinked upon exposure to the UV radiation to form a cross-linked region shaped according to the corresponding computer-generated cross-sectional pattern. It is not necessary that such regions be fully cured, as complete curing can be accomplished in a post- SLA UV cure.
  • steps 2 through 4 are repeated to gradually build up the desired prosthetic implant and, preferably, a support structure whose dimensions and locations are also incorporated into the CAD image.
  • select cross-linked regions of the layers of the prosthetic implant are offset to form a porous network
  • the prosthetic implant is washed in a bath to remove unpolymerized polymer and excess solvent.
  • the prosthetic implant is then exposed to UV radiation to complete cross-linking of the solid polymeric regions and bonding between the solid polymeric layers of the prosthetic implant.
  • step 1 of the method is preceded by a step comprising scanning a bone to be duplicated to produce data and converting such date into the three dimensional CAD image.
  • Suitable bone scanning methods include, but are not limited to, three dimensional CT scanning, MRI, film X-rays, and two-dimensional and three-dimensional ultrasound. Because of its accuracy, the preferred scanning method is CT.
  • the present methods provide prosthetic implants whose size and shape match the bone defect site geometry.
  • the prosthetic implants made in accordance with the present method also, advantageously, have a network of investing and interconnecting pores whose sizes and location can be precisely controlled during the fabrication process.
  • the present methods are a significantly faster means of producing a directly implantable prosthetic which can establish or return the defect site to desired function with acceptable aesthetics.
  • the present method allows fabrication of prosthetic implants having regions with different degrees of strength and resorption rate. Although the strength and the resorption rate may be uniform across the implant, it is expected that implants with regions that are variously loaded will have a higher degree of strength in some regions than others, h order to regenerate a loaded section, supporting structures will need to be arrayed next to porous spaces allowing bone ingrowth. These supporting structures may be non-degradable, slowly degradable, or relatively quickly degradable dependant on the needs of the defect site.
  • tissue must grow into the prosthetic implant from nearby host tissue, so good fit is highly desirable in areas where rapid host tissue ingrowth is a priority.
  • This present fabrication method provides significantly higher resolution control over the geometry of prosthetic implants that are produced. The higher resolution of the resulting prosthetic implant allows for complex design of internal geometries, including porous spaces, with can promote tissue ingrowth.
  • the present method is useful for fabricating prosthetic implants from polymers that are resorptive and from polymers that are not resorptive. Accordingly, the present fabrication method allows the formation of prosthetics with varying strength and degradation properties, by permitting the manufacturer to control the molecular weight and cross-linking density of the polymer used to form the prosthetic and/or to control the array and percentage of open space.
  • the present fabrication method also allows the design of surface textures which will influence cell attachment properties.
  • the present method allows the design of internal spaces in configurations which promote maturation of tissues, such as the lamellar arrangement of mature lamellar bone, hi addition to polymer, other materials (e.g., signaling molecules, cell attachment molecules) can be either incorporated into the polymer directly (i.e., part of the polymer chain) or in solution with the non-crosslinked polymer so that they become incorporated into the prosthetic implant during photo-crosslinking of the polymer chains.
  • Stereolithography is a sequential layering process. See, Jacobs, "Rapid Prototyping and Manufacturing-Fundamentals of Stereolithography,” (SME, Dearborn, Mich. 1992).
  • SLA is based on the use of a focused ultra-violet (UV) laser which is vector scanned over the top of a solution comprising chains of a photopolymerizable or photocurable polymer.
  • UV laser causes chains of the photocurable polymer to polymerize where the laser beam strikes the surface of the solution and to a certain depth below the surface of the solution.
  • the depth of polymerization depends on the power of the laser light. This results in the creation of a first solid polymeric layer at and just below the surface.
  • the solid polymeric layer is then lowered into the solution and the laser generated polymerization process is repeated for the generation of the next layer, and so on, until a plurality of superimposed layers forming a desired structure is obtained.
  • the structure corresponds to the three-dimensional CAD image.
  • Stereolithography can be performed in the presence of sensitive bioactive molecules.
  • prosthetic implants can be built that incorporate drugs.
  • a stereolithography instrument which can be modified and used in the present method is made and sold by 3D Systems, Inc., of Valencia, Calif under the model name 3D Systems,SLA 250.
  • the instrument comprises a servomechanism which controls the beam of the one or more UV lasers in the X and Y horizontal axis, and a tank for holding the solution comprising the photocurable polymer, photoinitiator, solvent, if necessary, and any other optional components to be incorporated into the prosthetic implant.
  • Located in the tank is a build platform which moves up and down along the Z axis.
  • the instrument further comprises a build platen for supporting layers of the cross-linked polymer.
  • the build platen which is situated on the build platform has a plurality of holes that allow the solution to flow therethrough when the platen is lowered and raised during the recoat cycle.
  • the initial solid layer of crosslinked polymer must adhere securely to the surface of the build platen to prevent the developing construct from floating freely in the solution which would adversely affect the dimensional and geometric accuracy of the prosthetic implant being built.
  • the diameter and pattern of the holes in the build platen is designed such that the construct is not dislodged from the build platen when the table is lowered during the recoat cycle.
  • the UV laser of the stereolithography instrument is tuned to polymerize the primary polymer to a depth of 0.1 mm (100 micron), and thereby to produce solid polymeric layers having a thickness of 0.1 mm, although prosthetic implants whose layers have a thickness greater than or less than 0.1 mm can also be prepared in accordance with the present method.
  • the solution comprises chains of at least one photocurable, bioerodable polymer (referred to hereinafter as the "primary" polymer).
  • the primary polymer can alter its mechanical properties, including its mechanical strength, it is contemplated that the fracture toughness of certain solid forms of the primary polymer will have a fracture toughness comparable to trabecular bone.
  • Methods of determining the fracture toughness of solid polymers are known in the art.
  • a solution that mimics a physiological environment e.g., phosphate-buffered saline, pH 7.4, 37 C
  • the solid form of the primary polymer does not produce an acidic spike.
  • porous photocrosslinked implants formed from the primary polymer biodegrade at a rate which is slow enough to allow for attachment and proliferation of progenitor cells and tissue ingrowth into the implant prior to a significant loss in mechanical strength of the implant.
  • a highly preferred primary polymer is poly(propylene fumarate) (PPF).
  • PPF is an unsaturated linear polyester that degrades in the presence of water into propylene glycol and fumaric acid, degradation products that are easily cleared from the human body by normal metabolic processes.
  • the fumarate double bonds in PPF are reactive and can form crosslinks.
  • the high mechanical strength and relatively slow degradation rate of cured or cross- linked PPF matrices makes them especially suitable for orthopedic application. Methods of synthesizing PPF are known in the art.
  • PPF resins in general, and PPF resins having a number average molecular weights (Mn) of 2500 and 5000 Da and a polydispersity index of less than 2, in particular, are described in U.S. Patent No. 6,124,373, which is incorporated herein in its entirety.
  • the solution comprises chains of one or more photocurable polymers other than the primary polymer, referred to hereinafter collectively as "secondary polymers" for preparing a composite prosthetic prosthetic implant.
  • the photocurable secondary polymers may be hydrophilic or hydrophobic. Although not necessary, it is anticipated that the photocrosslinked secondary polymers will be biodegradable.
  • the solution further comprises bioactive molecules.
  • bioactive molecules may be encapsulated in a drug delivery system, such as a biodegradable polymeric nanoparticle.
  • the bioactive molecules are linked to the uncured primary polymer either directly or through a hydrophilic spacer such as for example polyethylene glycol (PEG)
  • PEG polyethylene glycol
  • Methods of making PPF polymer chains that are linked to bioactive molecules without altering the molecular weight distribution of the PPF block are described in U.S. Patent No. 6,306,821 to Mikos et al which is specifically incorporated herein by reference.
  • the bioactive molecules may be dispersed in the solution for "entrapment" in the photo-crosslinked regions of the prosthetic implant during the photo-crosslinking process.
  • bioactive molecules include, but are not limited to molecules which promote epitaxial movement of the cells onto the prosthetic implant(e.g., calcium phosphates [CaP], proteins, such as cytokines, that are themselves signals to the cells, proteins belonging to the transforming growth factor superfamily, bone morphogenetic proteins, basic fibroblast factor, platelet derived growth factor, insulin like growth factor, extracellular molecules including osteopontin, ostenectin, osteocalcin, bone sialoprotein, peptides comprising 3 to 30 a ino acids, proteoglycans such as hyaluronic acid, and carbohydrates ,including starch, cellulose, and chitin.
  • CaP calcium phosphates
  • the solution further comprises at least one photo-initiator having an energy minimum (polymerization threshold) that matches the wavelength and laser energy employed in the method.
  • the method employs multiple lasers having different wavelengths and energy.
  • the solution comprises multiple photoinitiators
  • the solution further comprise a solvent for decreasing the viscosity of the solution.
  • the solvent is non- toxic .
  • the solvent can also be used to uniformly decrease the cross-linking density of the polymeric prosthetic implant and the mechanical strength of the polymeric prosthetic implant Addition of the solvent can also be used to increase the resorption rate of the prosthetic implant . Good results have been obtained using a solution of PPF and a DEF monomer resin as the solvent.
  • the prosthetic implant produced by the present method has solid regions comprising a bioerodable solid form of the primary polymer and registered interconnecting pores forming at least one channel, preferably a network of channels, extending from the exterior surface of the prosthetic implant to a predetermined interior region of the prosthetic implant.
  • Such channels permit migration of cells and tissue ingrowth into the prosthetic implant.
  • the channels have a diameter of from about 100 to 1000 microns.
  • the SLA construct comprises support structures, for example support rods, attached to the lowermost solid polymeric layer of the prosthetic implant.
  • Support structures are highly desirable for supporting all overhangs that cannot be built up from an already supported area only by surface tension of the most recently polyermized material.
  • the materials used to produce the prosthetic implant were; Poly(propylene fumerate)
  • the stereolithography machine (3D Systems SLA 250, Valencia, CA) consists of a servomechanism, which controls the beam of a UV laser in the X and Y horizontal axis, a tank of liquid monomer resin, and a motorized build platform moving in the Z-axis (i.e., vertically up and down in the tank of resin).
  • a build platen is located on the build platform on which the component is built as the laser beam polymerizes the resin one Z-layer at a time.
  • a 3D model of the prototype component to be manufactured was designed using a computer- aided-design software package (Pro/ENGFNEER 2000i) and exported as an STL file.
  • the STL file was then imported into the pre-processing software of the 3D Systems SLA 250 machine (Maestro). .
  • the 3D model volume was split in Z-axis into 0.004-inch horizontal slices; ' the X-axis and Y-axis profile data of each slice controls the focus point of the UV laser beam as it traces out the slice profile.
  • the UV laser cross-links or polymerizes the resin at the point of focus and produces a solid representation of the model at that particular Z-axis location.
  • the build of the PPF component was carried out in a 3 i -inch diameter culture dish that served to act as a build sub-tank to minimize the volume of material required and to prevent contamination of the PPF from the standard acrylic resin.
  • a custom fixture was screwed to the build platen and the build sub-tank locked in place on the fixture.
  • the PPF and photo-initiator mixture was poured into the dish to a depth of 2 mm.
  • the build platen was then loaded on to the build platform of the SLA machine. Prior to starting the build it the level of the PPF in the sub-tank was calibrated relative to the resin level in the standard build tank to ensure that the laser beam focused at the correct Z-depth prior to starting the build.
  • the prototype component build was only four Z-slices thick (0.016 inch) due to the limitation of the set-up. It was found that each Z-slice lost its registration with the preceding slice as a result of it floating freely in the liquid resin. Although registration was lost, the slices formed a solid component. Thus, there was cross-linking between the slices in addition to cross-linking with the two slices. The loss of registration between slices was expected and was a result of not including support structures in the built CAD file. Support structures are desirable to promote inter-slice registration and to prevent any overhanging surfaces from collapsing into the vat prior to their joining the rest of the object that is being generated.
  • the materials used to prepare the device were; Poly(propylene fumarate) (PPF) (Rice University-Bioengineering Department, Houston, TX), Diethyl fumarate (DEF) solvent, (Fisher Scientific, Fairlawn, NJ), Bisacylphosphine Oxide (BAPO) photoiniator (hrgacure 819) (CUBA Speciality Chemicals Additives Division, Tarrytown, NY). Materials were weighed and mixed in a standard fume cabinet. Two grams of BAPO were dissolved in 200g of DEF and mixed thoroughly. The BAPO/DEF mixture was then added to 280g of PPF and mixed thoroughly.
  • the quantities of DEF and PPF used resulted in a mixture that had similar viscosity properties to the native resin normally used with the SLA machine.
  • the DEF/PPF resin was allowed to stand for 30 minutes to allow air bubbles trapped in the mixture to dissipate.
  • the stereolithography machine used was an SLA 250/40 (3D Systems Valencia, CA).
  • the SLA 250/40 consists of a servomechanism, which controls the beam of a UV laser in the X and Y horizontal axis, a tank containing a liquid monomer resin, and a motorized build platform that is controlled in the Z-axis (Fig. 1).
  • the build platform is located so that it travels vertically up and down in the tank of resin.
  • a build table is located on the build platform on which the part is built as the laser beam polymerises the resin one Z-layer at a time.
  • a 3D model of the prototype part to be manufactured was designed using a 3D solid modelling computer-aided-design (CAD) software package, Pro/ENGINEER 2000i 2 (PTC, Needham, MA), and exported as an STL file.
  • the STL file was imported into the preprocessing software, Maestro (3D Systems Valencia, CA), on the 3D Systems SLA 250/40 console and was used to control the laser in the X-Y plane and the table in the Z-axis.
  • the 3D model volume was split in the Z-axis into 0.1 mm horizontal slices.
  • the X-axis and Y- axis profile data of each slice controls the focal point of the UV laser as it traces the slice profile.
  • the UV laser polymerizes the resin at the focal point and therefore progressively produces a solid representation of the model at that particular Z-slice location.
  • the manufacture of the PPF/DEF part was carried out in a custom-designed build fixture that incorporated a small build-tank and a build-table driven by the 3D Systems SLA 250/40 elevator.
  • the fixture was designed using Pro/ENGINEER 2000i 2 and manufactured in the Engineering Services Workshop at CWRU.
  • the small build-tank minimized the volume of resin required and also prevented contamination of the PPF/DEF resin from the standard SLA resin.
  • the custom fixture (Fig. 3) was located on the sides of the original build tank and levelled with set-screws to ensure smooth vertical motion of the build-table.
  • the custom build-table was coupled to the SLA 250/40's build-table by means of a small shaft enabling both tables to move in parallel, ensuring the correct Z-axis movement of the custom build-table during the experiment (Fig. 4).
  • the PPF/DEF mixture was poured into the custom build-tank to a depth of 70mm. Prior to starting the build, the level of the custom build-table was set relative to the PPF/DEF resin in the custom build-tank. This was conducted to ensure that the laser beam was focused at the correct Z-depth prior to starting the build.
  • the prototype part was designed with features that would test the ability to build solid protrusions (including four circular pads), holes and slots.
  • the overall thickness of the part was 4mm which would clearly show the ability to cross-link multiple layers and produce a part of a significant and physiologically relevant thickness.
  • the holes and slots would test the ability to reproduce geometric features that could be incorporated into the model to produce controlled porosity. i. Results
  • the PPF/DEF mixture was successfully cross-linked using the stereolithography process described and a multi-layer part was manufactured which closely matched the geometry of the CAD prototype model (Fig 5).
  • the holes, slots and protrusions showed clearly that registration between layers was maintained.
  • the side faces of the features were vertical and had relatively sharp edges between the vertical and horizontal faces of the top and bottom of the part.
  • the part achieved the total design thickness of 4mm and was built on supports that were 6.3mm high, indicating that approximately 80 layers in total were individually cross- linked together. Some of the supports (less than 10%) failed to attach to the build table and the part. Dimpling seen on the resulting part (Fig. 5) is on the underside. These dimples indicate where support structures were attached.
  • DEF resin has a very low viscosity so by adding this to the pure PPF resin, which has a high viscosity, the viscosity of the resin solution was lowered. Therefore, by controlling the proportions of DEF resin to PPF resin, the viscosity of the solution was controlled to be similar to that of native SLA resin.
  • the convex surface effect can also be minimized by re-engineering the build fixture with a modified design that locates the build tank so that the SLA machine wiper blade is able to conduct its intended function. This modification should allow for parts to be fabricated using higher viscosity DEF/PPF solutions.

Abstract

Processes for fabricating a customized, three-dimensional, bioerodable, polymeric prosthetic implant are provided. In a highly preferred embodiment, the prosthetic implant has a porous network. The method employs a sterolithography instrument, a solution comprising chains of one or more photocurable, bioerodable polymers and a photoinitiator, and a three-dimensional CAD image. In a highly preferred embodiment, the solution comprises poly (propylene) fumarate (PPF) and a solvent for controlling the viscosity of the solution. During the fabrication process, the solution is placed in a container in the stereolithography instrument. The container also holds a movable build platen for supporting each of the covalently bonded layers of the polymeric prosthetic implant that are formed when successive layers of the solution are exposed to UV light energy. The UV light energy is imparted to selected portions of each layer of the solution to produce a pattern of cross-linked and non-cross-linked polymeric regions corresponding to a cross-sectional image of the three-dimensional CAD image.

Description

FABRICATION OF A POLYMERIC PROSTHETIC IMPLANT
Reference to Related Application
This application claims priority to U.S. Provisional Application No. 60/284,803 filed on April l9, 2001.
Statement of Government Support
This invention is supported, at least in part, by Grant No. DE 13740 from the National Institutes of Health, U.S. Public Health Service. The U.S. government has certain rights in this invention.
Background of the Invention
Large skeletal defects frequently arise following reconstructive surgery for trauma, cancer resection, infection and congenital deformity. The standard clinical treatment for these defects is the transplantation of a bone graft derived from the patient (autograft) into the defect site. Although an autograft, typically, does not cause an immune response, it is associated with several disadvantages including donor site morbidity and limited availability. Furthermore, it is possible that an autograft will not successfully vascularize in the new site, leading to its resorption and/or infection of the graft site.
Other treatments may be used to replace the defect. These include implantation of a bone cement (calcium phosphate, acrylic [e.g., PMMA], or plastic [e.g., polyethylene]) or a metal prosthetic. Unfortunately, the long term persistence of these materials can lead to complications at and surrounding the defect site. For example, because such materials may have a different modulus and strength than the surrounding tissue, implantation of prosthetic devices made from such materials into the defect site can lead to damage of the surrounding tissues. Moreover, prosthetic devices made from these materials do not (a) revascularize or allow for tissue regeneration in the defect site, (b) integrate with the existing host bone, or (c) undergo subsequent remodeling in response to evolving mechanical (i.e., ambulatory loading or protection of internal organs) needs. This leads to problems with protective strength and aesthetics as the host bone remodels around the implanted prosthetic. The problems are magnified by the post-surgical need to protect the brain or other internal organs covered by prosthetic from infection and trauma during the healing process.
The inadequacies of the current prosthetics have led to an investigation of prosthetics that act as porous scaffold for attachment and proliferation of tissue progenitor (e.g., bone progenitor) cells. It has been proposed that such scaffolds be made from a biodegradeable polymer that slowly degrades away, eventually leaving a defect site that has been repaired by the cells which migrate into and attach to the scaffold. Prior to its degradation, the scaffold serves not only to provide a surface for attachment of the progenitor bone cells, but also to allow in nutrients and to support any biomechanical functions (ambulatory loading or protection).
Polymeric scaffolds have been fabricated by a chemical cross-linking process or, more recently, by photocrosslihking the liquid polymeric material in a transparent mold. Molds do not facilitate the formation of internal spaces such as pores. To overcome this deficiency, investigators have tried to stir salt crystals into the polymer and later leach it out with water. The salt crystal space is left as a pore, but the surface texture and arrangement of, pores is not homogenous and geometrically may not be conducive to cell attachment, proliferation, or maturation, as well as vascular ingrowth
Accordingly, it is desirable to have new methods for fabricating biodegradable polymeric prosthetics for treating critical size bone defects. It is also desirable to have a method which provides a prosthetic that not only maintains its shape and protective strength during the healing process but also encourages bone ingrowth and incorporation of the prosthetic with the host bone. It is also desirable to have a method for fabricating a prosthetic which comprises a polymer that, when prosthetic implanted into a defect site, does not degrade into by-products that have serious adverse affects on the cells and tissues in contact with the prosthetic.
Summary of the Invention The present invention provides a method of fabricating a customized three- dimensional prosthetic implant for use in repairing a critical size tissue defect, particularly a critical size bone defect in a patient As used herein the term "critical size bone defect" refers to a bone defect that the patient cannot heal without assistance. As used herein the term "customized" refers to a prosthetic prosthetic implant whose size and shape dimensionally matches the bone defect site in the patient. Preferably, such prosthetic comprises a series of interconnecting pores that provide at least one channel, more preferably a network of interconnecting channels, leading from the exterior surface of the prosthetic implant to a predetermined location in the interior of the prosthetic implant. The pores and channels are defined by surfaces which provide points of bone or vascular progenitor cells. The present method comprise the following steps: providing a solution comprising chains of a photopolymerizable, bioerodable, liquid polymeric materials (referred to hereinafter as a " primary polymer") and a photoinitiator for promoting photocrosslinking of the primary polymer; providing a stereolithography instrument comprising a UV laser for activating the photoinitiator and photocrosslinking the primary polymer; providing a CAD image of the desired three-dimensional prosthetic prosthetic implant, wherein said CAD image is readable by the stereolithography instrument; depositing the solution in successive layers on a build platen in the stereolithography instrument; and photocrosslinking the primary polymer in each of the successive layers according to corresponding cross-sectional patterns derived from the CAD image. The fabrication method may further comprise an earlier step of scanning a bone to be duplicated to provide data and converting the data into the three dimensional CAD image. In one highly preferred embodiment of the present method, the primary polymer is a poly (propylene fumarate)(hereinafter "PPF"), and the solution further comprises a solvent for reducing the viscosity of the PPF liquid. Optionally, the solution further comprises chains of one or more additional photopolymerizable polymers (referred to hereinafter as the "secondary polymer") for preparing a composite prosthetic implant.
The present invention also provides an prosthetic implant prepared in accordance with the present method. Such prosthetic implant comprises solid regions comprising the photocrosslinked primary polymer and has a network of interconnecting pores and channels leading from the exterior surface to an interior location in the prosthetic prosthetic implant. Preferably, the diameter of the pores and channels is from about 100 microns to about 1000 microns. In certain embodiments, the prosthetic implant is a composite prosthetic prosthetic implant wherein a portion or all of the solid regions of the prosthetic prosthetic implant comprise a photcrosslinked primary polymer and a photocrosslinked secondary polymer, hi other embodiments, the prosthetic prosthetic implant is a composite prosthetic prosthetic implant wherein a first group of solid regions in the prosthetic implant comprise the photocrosslinked primary polymer and a second group of solid regions in the prosthetic implant comprise a photocrosslinked secondary polymer. The prosthetic implant may also comprise bioactive molecules.
Brief Description of the Figures
Figure 1: Laser Curing Device (3D Systems 250/40 SLA): A CAD file is converted into slice data. A high resolution laser beam moves over a vat of resin. The resin is hardened to a prescribed depth of 0.1 mm (100 microns), one slice at a time. Elevator platfonn moves down 0.1 mm after each layer is polymerised. Adjacent layers polymerise to one another, held in registration by supports bound to the elevator (build) platen. (Image Copyright 3D Systems,
Valencia, CA.)
Figure 2: Pro/ENGINEER rendered CAD image of prototype PPF construct: The series of slots and projections test the inter-slice PPF registration. Overall dimensions are 50mm diameter x 4mm thick.
Figure 3: Custom mini-build tank from above: It is located on the 3D System SLA 250 machine. Note that it takes advantage of the 3D systems elevator hardware but, at this time, not the wiper blade. A movie at http://neurosurgery.cwru.edu/imaging/public/index.html shows how it works.
Figure 4: Custom mini-build tank cross-sectional view: A CAD rendered image showing a section through the custom mini-build tank.
Figure 5: SLA manufactured PPF/DEF prototype: This part was generated from CAD model data fed to an SLA 250/40. The mottled (dots and lines) on undersurface indicate support structures that were previously attached to the mini-tank build platen.
Detailed Description of the Invention
The present invention provides a process for fabricating a customized, three- dimensional, bioresorbable, polymeric prosthetic implant, particularly a bone prosthetic implant, hi a highly preferred embodiment, the prosthetic implant has a porous network. The method employs a sterolithography instrument, a solution comprising chains of one or more photocurable, bioerodable polymers and a photoinitiator, and a three-dimensional CAD image, h a highly preferred embodiment, the solution comprises poly (propylene) fumarate (PPF) and a solvent for controlling the viscosity of the solution. Optionally, the solution comprises chains of a second photocurable polymer or chains of a second photocurable polymer and a second photoinitiator. Preferably, the solution further comprises bioactive molecules that promote attachment, proliferation, and/or differentiation of vascular and/or bone progenitor cells. During the fabrication process, the solution is placed in a container in the stereolithography instrument. The container also holds a movable build platen for supporting each of the covalently bonded layers of the polymeric prosthetic implant that are formed when successive layers of the solution are exposed to UV light energy. The UV light energy is imparted to selected portions of each layer of the solution to produce a pattern of cross-linked and non-cross-linked polymeric regions corresponding to a cross-sectional image of the three-dimensional CAD image. At some point in the process the non-cross- linked polymeric resin in the prosthetic implant is washed away DEFINITIONS
The singular forms "a," "an" and "the" are used herein to include the plural unless the content clearly dictates otherwise. Thus, for example, reference to "a PPF polymer" includes more than one such polymer, reference to "a layer" includes more than one layer, and the like.
The term "bioerodable" as used herein refers to a polymer whose solid form degrades by surface erosion or bioerosion rather than bulk degradation. Two distinct types of degradation can occur with implanted solid polymers. One type of degradation is bulk degradation, in which the polymer degrades in a fairly uniform manner throughout the matrix. The prevailing mechanism of bulk degradation is hydrolysis of the hydrolytically unstable polymer backbone. First, water penetrates the bulk of the solid polymeric implant, preferentially attacking chemical bonds in the amorphous phase and converting long polymer chains into shorter water-soluble fragments. This results, initially, in a reduction in molecular weight (Mn) without an immediate change in physical properties. Once the polymeric implant begins to fragment, a reduction in mechanical strength of the polymer occurs. Next, enzymatic attack and metabolization of the fragments occurs. At this point, the rate at which the water penetrates the implant exceeds that at which the polymer is converted into water- soluble materials, and the remaining implant comes apart.
The second type of degradation is surface erosion, which is also called bioerosion. Bioerosion occurs when the rate at which water penetrates the prosthetic implant is slower than the rate of the conversion of the polymer into water-soluble materials. Bioerosion results in a thinning of the prosthetic implant over time, though the prosthetic implant's bulk integrity is maintained.
PPF is a bioerodable polymer. PLA, PGA, and PLGA may degrade in bulk and, therefore, for the purposes of the present invention, are not considered to be bioerodable polymers.
The term "CAD" is used herein in its broadest sense to include all manner of computer aided design systems, including pure CAD systems, CAD/CAM systems, and the like, provided that such systems are used at least in part to develop or process a model of a three- dimensional polymeric bone prosthetic implant. The term "three-dimensional polymeric prosthetic implant" is used herein to mean any polymeric prosthetic implant that substantially retains its intended function and shape when removed from an external support.
The term "cross-sectional pattern" is used herein to mean a representation of a cross-section of the prosthetic implant being built. Generally speaking, the cross-sectional pattern will be a complete vertical cross-section, because most prosthetic implants are contemplated to be produced one complete layer at a time, in a vertical, stepwise fashion.
The terms "photocrosshnk" and "photocure" as used herein are interchangeable and refer to a process that is initiated by exposure of a polymer to UV radiation in the presence of a photinitiator, and that results in the formation of chemical links between molecular chains of the polymer. In accordance with the present methods, the bioresorbable polymers which are used to prepare the present prosthetic implants are uncrosslinked, or uncured, prior to exposure to activating UV radiation, hi accordance with the present methods, the final prosthetic implant comprises select and predetermined solid regions of a photocrosslinked or photocured polymer, preferably a photocrosslinked or photocured PPF polymer.
The term "successive layer" as used herein refers to the layer of solution that is sequentially deposited on the build platen or the previous photocrosslinked layer of the polymeric prosthetic implant during the stereolithographic procedure, hi accordance with the present invention, there is inter layer bonding between each of the photocrosslinked layers of the polymeric prosthetic implant.
"Ultraviolet or UV radiation" is radiation in the region of the electromagnetic spectrum including wave-lengths from 100 to 3900 angstroms.
In step 1 of the present method, a computer representation or three-dimensional "image" of the prosthetic implant to be formed, including its internal network of pores is generated using a CAD/CAM software system. The software then preferably generates an STL file for use in a sterolithography instrument. The STL file is converted into "slice" data corresponding to vertical cross-sectional patterns (X-Y slices of Z thickness) of the desired prosthetic implant, a process termed stereolithography (SLA). In step 2, a layer of the solution is applied either to the work surface of the build platen or to a previous photocrosslinked polymeric layer. Thereafter, the layer is leveled to a desired thickness that corresponds to the thickness of the "slice" generated by the computer and the depth of polymerization of the particular laser/ initiator/ polymer combination used .
h step 3, appropriate slice data from step 1 is fed to a selective photoexposure device, which in turn exposes the layer of solution deposited in step 2 to one or more scanning UV lasers according to the corresponding cross-sectional pattern derived from the three- dimensional CAD image. Appropriate intensity and duration of the exposure is contemplated to be established experimentally. Nevertheless, it may be understood that suitable values for these parameters will vary as a function of numerous factors, including the nature of the photocurable polymers in the solution, the amount and activity of the photoinitiator, and the thickness and transparency of each layer to the radiation. Such exposure is selected to provide a suitable, predetermined degree of cross-linking between the polymeric chains of the photocurable polymer, while still permitting adequate bonding between adjacent layers. Specific exposure parameters are given below, but in general it is contemplated that intensity will correspond to the wavelength at which the photoinitiator in the solution has maximum absorbance.
Variation of the laser intensity or traversal speed can be used to vary the cross-link density within a layer so that the physical properties of the solid polymeric regions can be varied from position to position within the prosthetic implant. Cross-linking density can also be altered by varying the ratio of the photocurable polymer to solvent in the solution and by employing two or more photocurable polymers having different molecular weights and different numbers of cross-linking sites along the polymer chains.
In step 4, the PPF oligomeric and polymeric chains in the solution are photocrosslinked upon exposure to the UV radiation to form a cross-linked region shaped according to the corresponding computer-generated cross-sectional pattern. It is not necessary that such regions be fully cured, as complete curing can be accomplished in a post- SLA UV cure.
In step 5, steps 2 through 4 are repeated to gradually build up the desired prosthetic implant and, preferably, a support structure whose dimensions and locations are also incorporated into the CAD image. Preferably, during the build up of the prosthetic implant, select cross-linked regions of the layers of the prosthetic implant are offset to form a porous network After removal from the stereolithography instrument, the prosthetic implant is washed in a bath to remove unpolymerized polymer and excess solvent. Preferably, the prosthetic implant is then exposed to UV radiation to complete cross-linking of the solid polymeric regions and bonding between the solid polymeric layers of the prosthetic implant.
Optionally, step 1 of the method is preceded by a step comprising scanning a bone to be duplicated to produce data and converting such date into the three dimensional CAD image. Suitable bone scanning methods include, but are not limited to, three dimensional CT scanning, MRI, film X-rays, and two-dimensional and three-dimensional ultrasound. Because of its accuracy, the preferred scanning method is CT.
Advantageously, the present methods provide prosthetic implants whose size and shape match the bone defect site geometry. The prosthetic implants made in accordance with the present method also, advantageously, have a network of investing and interconnecting pores whose sizes and location can be precisely controlled during the fabrication process. Moreover, the present methods are a significantly faster means of producing a directly implantable prosthetic which can establish or return the defect site to desired function with acceptable aesthetics.
The present method allows fabrication of prosthetic implants having regions with different degrees of strength and resorption rate. Although the strength and the resorption rate may be uniform across the implant, it is expected that implants with regions that are variously loaded will have a higher degree of strength in some regions than others, h order to regenerate a loaded section, supporting structures will need to be arrayed next to porous spaces allowing bone ingrowth. These supporting structures may be non-degradable, slowly degradable, or relatively quickly degradable dependant on the needs of the defect site.
For optimum performance, tissue must grow into the prosthetic implant from nearby host tissue, so good fit is highly desirable in areas where rapid host tissue ingrowth is a priority. This present fabrication method provides significantly higher resolution control over the geometry of prosthetic implants that are produced. The higher resolution of the resulting prosthetic implant allows for complex design of internal geometries, including porous spaces, with can promote tissue ingrowth. The present method is useful for fabricating prosthetic implants from polymers that are resorptive and from polymers that are not resorptive. Accordingly, the present fabrication method allows the formation of prosthetics with varying strength and degradation properties, by permitting the manufacturer to control the molecular weight and cross-linking density of the polymer used to form the prosthetic and/or to control the array and percentage of open space. The present fabrication method also allows the design of surface textures which will influence cell attachment properties. Finally, the present method allows the design of internal spaces in configurations which promote maturation of tissues, such as the lamellar arrangement of mature lamellar bone, hi addition to polymer, other materials (e.g., signaling molecules, cell attachment molecules) can be either incorporated into the polymer directly (i.e., part of the polymer chain) or in solution with the non-crosslinked polymer so that they become incorporated into the prosthetic implant during photo-crosslinking of the polymer chains.
STEREOLITHOGRAPHY
Stereolithography (SL) is a sequential layering process. See, Jacobs, "Rapid Prototyping and Manufacturing-Fundamentals of Stereolithography," (SME, Dearborn, Mich. 1992). SLA is based on the use of a focused ultra-violet (UV) laser which is vector scanned over the top of a solution comprising chains of a photopolymerizable or photocurable polymer. The UV laser causes chains of the photocurable polymer to polymerize where the laser beam strikes the surface of the solution and to a certain depth below the surface of the solution. The depth of polymerization depends on the power of the laser light. This results in the creation of a first solid polymeric layer at and just below the surface. The solid polymeric layer is then lowered into the solution and the laser generated polymerization process is repeated for the generation of the next layer, and so on, until a plurality of superimposed layers forming a desired structure is obtained. In the present method, the structure corresponds to the three-dimensional CAD image. Stereolithography can be performed in the presence of sensitive bioactive molecules. Thus, in accordance with the present invention, prosthetic implants can be built that incorporate drugs.
STEREOLITHOGRAPHY INSTRUMENT
A stereolithography instrument which can be modified and used in the present method is made and sold by 3D Systems, Inc., of Valencia, Calif under the model name 3D Systems,SLA 250. The instrument comprises a servomechanism which controls the beam of the one or more UV lasers in the X and Y horizontal axis, and a tank for holding the solution comprising the photocurable polymer, photoinitiator, solvent, if necessary, and any other optional components to be incorporated into the prosthetic implant. Located in the tank is a build platform which moves up and down along the Z axis. As modified, the instrument further comprises a build platen for supporting layers of the cross-linked polymer. The build platen, which is situated on the build platform has a plurality of holes that allow the solution to flow therethrough when the platen is lowered and raised during the recoat cycle. However, the initial solid layer of crosslinked polymer must adhere securely to the surface of the build platen to prevent the developing construct from floating freely in the solution which would adversely affect the dimensional and geometric accuracy of the prosthetic implant being built. Specifically, the diameter and pattern of the holes in the build platen is designed such that the construct is not dislodged from the build platen when the table is lowered during the recoat cycle.
Preferably, the UV laser of the stereolithography instrument is tuned to polymerize the primary polymer to a depth of 0.1 mm (100 micron), and thereby to produce solid polymeric layers having a thickness of 0.1 mm, although prosthetic implants whose layers have a thickness greater than or less than 0.1 mm can also be prepared in accordance with the present method.
SOLUTION
The solution comprises chains of at least one photocurable, bioerodable polymer (referred to hereinafter as the "primary" polymer). Although altering the polymer molecular weight of the primary polymer can alter its mechanical properties, including its mechanical strength, it is contemplated that the fracture toughness of certain solid forms of the primary polymer will have a fracture toughness comparable to trabecular bone. Methods of determining the fracture toughness of solid polymers are known in the art. When incubated in a solution that mimics a physiological environment (e.g., phosphate-buffered saline, pH 7.4, 37 C), the solid form of the primary polymer does not produce an acidic spike. In addition, porous photocrosslinked implants formed from the primary polymer biodegrade at a rate which is slow enough to allow for attachment and proliferation of progenitor cells and tissue ingrowth into the implant prior to a significant loss in mechanical strength of the implant.
A highly preferred primary polymer is poly(propylene fumarate) (PPF). PPF is an unsaturated linear polyester that degrades in the presence of water into propylene glycol and fumaric acid, degradation products that are easily cleared from the human body by normal metabolic processes. The fumarate double bonds in PPF are reactive and can form crosslinks. The high mechanical strength and relatively slow degradation rate of cured or cross- linked PPF matrices makes them especially suitable for orthopedic application. Methods of synthesizing PPF are known in the art. For example, a method of synthesizing PPF resins, in general, and PPF resins having a number average molecular weights (Mn) of 2500 and 5000 Da and a polydispersity index of less than 2, in particular, are described in U.S. Patent No. 6,124,373, which is incorporated herein in its entirety.
Optionally, the solution comprises chains of one or more photocurable polymers other than the primary polymer, referred to hereinafter collectively as "secondary polymers" for preparing a composite prosthetic prosthetic implant. The photocurable secondary polymers may be hydrophilic or hydrophobic. Although not necessary, it is anticipated that the photocrosslinked secondary polymers will be biodegradable.
Preferably, the solution further comprises bioactive molecules. Such bioactive molecules may be encapsulated in a drug delivery system, such as a biodegradable polymeric nanoparticle. Alternatively, the bioactive molecules are linked to the uncured primary polymer either directly or through a hydrophilic spacer such as for example polyethylene glycol (PEG) Methods of making PPF polymer chains that are linked to bioactive molecules without altering the molecular weight distribution of the PPF block are described in U.S. Patent No. 6,306,821 to Mikos et al which is specifically incorporated herein by reference. In addition, the bioactive molecules may be dispersed in the solution for "entrapment" in the photo-crosslinked regions of the prosthetic implant during the photo-crosslinking process.
Examples of such bioactive molecules include, but are not limited to molecules which promote epitaxial movement of the cells onto the prosthetic implant(e.g., calcium phosphates [CaP], proteins, such as cytokines, that are themselves signals to the cells, proteins belonging to the transforming growth factor superfamily, bone morphogenetic proteins, basic fibroblast factor, platelet derived growth factor, insulin like growth factor, extracellular molecules including osteopontin, ostenectin, osteocalcin, bone sialoprotein, peptides comprising 3 to 30 a ino acids, proteoglycans such as hyaluronic acid, and carbohydrates ,including starch, cellulose, and chitin.
The solution further comprises at least one photo-initiator having an energy minimum (polymerization threshold) that matches the wavelength and laser energy employed in the method. Optionally, the method employs multiple lasers having different wavelengths and energy. Under these conditions, the solution comprises multiple photoinitiators When PPF is used as the primary polymer, it is preferred that the solution further comprise a solvent for decreasing the viscosity of the solution. Preferably, the solvent is non- toxic .The solvent can also be used to uniformly decrease the cross-linking density of the polymeric prosthetic implant and the mechanical strength of the polymeric prosthetic implant Addition of the solvent can also be used to increase the resorption rate of the prosthetic implant . Good results have been obtained using a solution of PPF and a DEF monomer resin as the solvent.
Structure of the SLA Construct and Prosthetic implant
The prosthetic implant produced by the present method has solid regions comprising a bioerodable solid form of the primary polymer and registered interconnecting pores forming at least one channel, preferably a network of channels, extending from the exterior surface of the prosthetic implant to a predetermined interior region of the prosthetic implant. Such channels permit migration of cells and tissue ingrowth into the prosthetic implant. For bone prosthetic implants, it is preferred that the channels have a diameter of from about 100 to 1000 microns.
Following its removal from the stereolithography instrument and prior to its exposure to a post-SLA UV cure, the SLA construct comprises support structures, for example support rods, attached to the lowermost solid polymeric layer of the prosthetic implant. Support structures are highly desirable for supporting all overhangs that cannot be built up from an already supported area only by surface tension of the most recently polyermized material.
The following examples are for illustration only and are not intended to limit the scope of the invention.
Example 1
Materials and Methods
The materials used to produce the prosthetic implant were; Poly(propylene fumerate)
(PPF) (prepared in the Bioengineering Department, Rice University, Houston, TX), Bisacylphosphine Oxide (BAPO) (Irgacure 819) (CIBA Specialty Chemicals Additives Division, Tarrytown, NY), and Chloroform C-295 (Fisher Scientific, Fair Lawn, NJ). Materials were weighed and mixed in a standard fume cabinet; One gm of BAPO was dissolved in lOgm of chloroform and mixed thoroughly, 0.5 ml of the BAPO/chl mixture was added to lOgm of PPF and mixed thoroughly. The resulting resin mixture was poured into a 3 >-inch diameter culture dish to a depth of 2mm.
The stereolithography machine (3D Systems SLA 250, Valencia, CA) consists of a servomechanism, which controls the beam of a UV laser in the X and Y horizontal axis, a tank of liquid monomer resin, and a motorized build platform moving in the Z-axis (i.e., vertically up and down in the tank of resin). A build platen is located on the build platform on which the component is built as the laser beam polymerizes the resin one Z-layer at a time. A 3D model of the prototype component to be manufactured was designed using a computer- aided-design software package (Pro/ENGFNEER 2000i) and exported as an STL file. The STL file was then imported into the pre-processing software of the 3D Systems SLA 250 machine (Maestro). .The 3D model volume was split in Z-axis into 0.004-inch horizontal slices;' the X-axis and Y-axis profile data of each slice controls the focus point of the UV laser beam as it traces out the slice profile. The UV laser cross-links or polymerizes the resin at the point of focus and produces a solid representation of the model at that particular Z-axis location.
The build of the PPF component was carried out in a 3 i -inch diameter culture dish that served to act as a build sub-tank to minimize the volume of material required and to prevent contamination of the PPF from the standard acrylic resin. To carry out the build, a custom fixture was screwed to the build platen and the build sub-tank locked in place on the fixture. The PPF and photo-initiator mixture was poured into the dish to a depth of 2 mm. The build platen was then loaded on to the build platform of the SLA machine. Prior to starting the build it the level of the PPF in the sub-tank was calibrated relative to the resin level in the standard build tank to ensure that the laser beam focused at the correct Z-depth prior to starting the build.
The support structures, which normally precede the first Z-slice proper of the component, were eliminated. The lack of support structures limited the number of Z-slices built because without the supports the solid component produced by each lased slice would be free to 'float' within the liquid polymer.
Results and Discussion
The results demonstrated that a solid polymeric PPF device could be successfully manufactured using the sterelithographic rapid prototyping process by cross-linking the biocompatible, biodegradable polymeric material, (polypropylene fumerate) (PPF) mixed with a suitable photo-initiator (bisacylphosphine oxide) (BAPO) and UV laser light (325nm wavelength).
The prototype component build was only four Z-slices thick (0.016 inch) due to the limitation of the set-up. It was found that each Z-slice lost its registration with the preceding slice as a result of it floating freely in the liquid resin. Although registration was lost, the slices formed a solid component. Thus, there was cross-linking between the slices in addition to cross-linking with the two slices. The loss of registration between slices was expected and was a result of not including support structures in the built CAD file. Support structures are desirable to promote inter-slice registration and to prevent any overhanging surfaces from collapsing into the vat prior to their joining the rest of the object that is being generated.
These results indicate that internal porosity of the polymeric prosthetic implant should be controllable using the present method. Controlled porosity would allow communication of any desired spaces. This control over prosthetic implant internal geometry allows construction of custom designed prosthetic prosthetic implants with complex internal structures suitable for optimal stem cell, growth factor, vascular promotion factor, and immunological management factor seeding, as well as desired host cell recruitment, which together promote maturation of cells to adult tissue configurations and prosthetic implant resorption..
Example 2
Materials and Methods
The materials used to prepare the device were; Poly(propylene fumarate) (PPF) (Rice University-Bioengineering Department, Houston, TX), Diethyl fumarate (DEF) solvent, (Fisher Scientific, Fairlawn, NJ), Bisacylphosphine Oxide (BAPO) photoiniator (hrgacure 819) (CUBA Speciality Chemicals Additives Division, Tarrytown, NY). Materials were weighed and mixed in a standard fume cabinet. Two grams of BAPO were dissolved in 200g of DEF and mixed thoroughly. The BAPO/DEF mixture was then added to 280g of PPF and mixed thoroughly. The quantities of DEF and PPF used resulted in a mixture that had similar viscosity properties to the native resin normally used with the SLA machine. The DEF/PPF resin was allowed to stand for 30 minutes to allow air bubbles trapped in the mixture to dissipate.
Method
The stereolithography machine used was an SLA 250/40 (3D Systems Valencia, CA). The SLA 250/40 consists of a servomechanism, which controls the beam of a UV laser in the X and Y horizontal axis, a tank containing a liquid monomer resin, and a motorized build platform that is controlled in the Z-axis (Fig. 1). The build platform is located so that it travels vertically up and down in the tank of resin. A build table is located on the build platform on which the part is built as the laser beam polymerises the resin one Z-layer at a time.
A 3D model of the prototype part to be manufactured (Fig. 2) was designed using a 3D solid modelling computer-aided-design (CAD) software package, Pro/ENGINEER 2000i2 (PTC, Needham, MA), and exported as an STL file. The STL file was imported into the preprocessing software, Maestro (3D Systems Valencia, CA), on the 3D Systems SLA 250/40 console and was used to control the laser in the X-Y plane and the table in the Z-axis. The 3D model volume was split in the Z-axis into 0.1 mm horizontal slices. The X-axis and Y- axis profile data of each slice controls the focal point of the UV laser as it traces the slice profile. The UV laser polymerizes the resin at the focal point and therefore progressively produces a solid representation of the model at that particular Z-slice location.
The manufacture of the PPF/DEF part was carried out in a custom-designed build fixture that incorporated a small build-tank and a build-table driven by the 3D Systems SLA 250/40 elevator. The fixture was designed using Pro/ENGINEER 2000i2 and manufactured in the Engineering Services Workshop at CWRU.
The small build-tank minimized the volume of resin required and also prevented contamination of the PPF/DEF resin from the standard SLA resin. The custom fixture (Fig. 3) was located on the sides of the original build tank and levelled with set-screws to ensure smooth vertical motion of the build-table. The custom build-table was coupled to the SLA 250/40's build-table by means of a small shaft enabling both tables to move in parallel, ensuring the correct Z-axis movement of the custom build-table during the experiment (Fig. 4). The PPF/DEF mixture was poured into the custom build-tank to a depth of 70mm. Prior to starting the build, the level of the custom build-table was set relative to the PPF/DEF resin in the custom build-tank. This was conducted to ensure that the laser beam was focused at the correct Z-depth prior to starting the build.
The prototype part was designed with features that would test the ability to build solid protrusions (including four circular pads), holes and slots. The overall thickness of the part was 4mm which would clearly show the ability to cross-link multiple layers and produce a part of a significant and physiologically relevant thickness. The holes and slots would test the ability to reproduce geometric features that could be incorporated into the model to produce controlled porosity. i. Results
The PPF/DEF mixture was successfully cross-linked using the stereolithography process described and a multi-layer part was manufactured which closely matched the geometry of the CAD prototype model (Fig 5). The holes, slots and protrusions showed clearly that registration between layers was maintained. The side faces of the features were vertical and had relatively sharp edges between the vertical and horizontal faces of the top and bottom of the part. The part achieved the total design thickness of 4mm and was built on supports that were 6.3mm high, indicating that approximately 80 layers in total were individually cross- linked together. Some of the supports (less than 10%) failed to attach to the build table and the part. Dimpling seen on the resulting part (Fig. 5) is on the underside. These dimples indicate where support structures were attached. After removal from the SLA 250/40 machine, the part was post-cured for 2 hours in a UV enclosure to ensure complete cross- linking of the material. ii. Discussion
This example successfully demonstrates the feasibility of using the stereolithography process to build and control 3D multi-layer parts made from a biodegradable, biocompatible resin. In the current example, it was a significant achievement to manufacture a part that was of a physiologically relevant size (4mm maximum thickness and 50mm diameter) using a commercially available SLA system. These results provide evidence that the present SLA method is a viable process to manufacture large custom scaffolds for tissue engineered prosthetic prosthetic implants.
The differences observed between the CAD model and the SLA fabricated part were mostly due to the limitations of the custom-designed build tank. The custom-designed build tank prevented the resin from being leveled after each recoating cycle with the wiper blade of the SLA machine because the top of the tank was located above the level of the wiper blade. Our initial tests were conducted with high molecular weight, pure PPF that had a high viscosity and surface tension. After each recoat cycle, a convex mound formed over the part surfaces prior to the laser drawing the next slice profile. This resulted in the part having increasingly convex, instead of flat, horizontal surfaces on its upper face. Avoiding this type of "wave" action is the intent of the wiper blade. To minimize the convex-surface effect, a solution of DEF/PPF resin was used. DEF resin has a very low viscosity so by adding this to the pure PPF resin, which has a high viscosity, the viscosity of the resin solution was lowered. Therefore, by controlling the proportions of DEF resin to PPF resin, the viscosity of the solution was controlled to be similar to that of native SLA resin. The convex surface effect can also be minimized by re-engineering the build fixture with a modified design that locates the build tank so that the SLA machine wiper blade is able to conduct its intended function. This modification should allow for parts to be fabricated using higher viscosity DEF/PPF solutions.

Claims

CLAIMSWhat is claimed is:
1. A process for fabricating a customized three-dimensional prosthetic implant, comprising the steps of:
(a) providing a solution comprising chains of a primary photocurable, bioerodable polymer, a primary photoinitiator for promoting photocrosslinking of the chains of the primary polymer, and a solvent, wherein the primary polymer is poly(propylene fumarate)(PPF);
(b) providing a stereolithography instrument comprising a primary UV laser for activating the primary photoinitiator and photocrosslinking the PPF chains;
(c) providing a three dimensional CAD image of a desired three-dimensional prosthetic implant, wherein the three-dimensional CAD image is readable by the stereolithography instrument;
(d) depositing the solution in successive layers on a build platen in the stereolithography instrument; and
(e) photocrosslinking at least a portion of the PPF chains in each of the successive layers according to corresponding cross-sectional patterns derived from the three dimensional CAD image to provide a three dimensional construct whose size and external and internal shapes correspond to the three dimensional CAD image.
2. The method of claim 1 wherein the solution comprises chains of a secondary photocurable polymer and wherein the process comprises photocrosslinking PPF chains and chains of the secondary photocurable polymer to provide a composite prosthetic implant.
3. The method of claim 1 wherein the solution comprises chains of a secondary photocurable polymer and a secondary photoinitator for initiating photocrosslinking of the secondary photocurable polymer; wherein the stereolithography instrument comprises a secondary UV laser for activating the secondary photoinitiator and photocrosslinking the secondary photocurable polymer, wherein the wavelength of radiation emitted by the secondary UV laser is different from the wavelength of radiation emitted by the primary UV laser, and wherein the process comprises photocrosslinking the PPF polymer by activating the primary photoinitiator with the primary UV laser and photocrosslinking the secondary photocurable polymer by activating the secondary photoinitiator with the secondary UV laser to provide a composite prosthetic implant.
4. The process of claim 1 wherein the PPF chains have bioactive molecules attached thereto
5. The process of claim 1 wherein the three dimensional CAD image has a series of interconnecting pores forming at least one channel leading from the exterior surface of the three dimensional CAD image to a predetermined location in the interior of the three dimensional CAD image, and wherein the construct has a corresponding series of interconnecting pores forming at least one channel leading from the exterior surface of the construct to corresponding location in the interior of the construct.
6. The process of claim 1 wherein the desired three-dimensional CAD image has a network of intercomiecting channels, and wherein the construct has a corresponding network of interconnecting channels for promoting attachment of cells and ingrowth of tissue.
7. The process of claim 5 wherein the diameter of the pores and channels is from about 100 to 1000 microns.
8. The process of claim 5 wherein the diameter of the channels is from about 100 to 1000 microns.
9. The process of claim 1 further comprising the steps of washing the construct to substantially remove the solvent and non-crosslinked PPF chains, and exposing the construct to UV radiation to fully cure partially cured regions of the construct.
10. The process of claim 1 wherein step (a) is preceded by a step comprising scanning a bone to be duplicated to produce data and converting such date into the three dimensional CAD image
11. The proces of claim 1 wherein said scanning is three dimensional CT scanning.
12. The process of claim 1 wherein the solvent is non-toxic
13. The process of claim 1 wherein the solvent comprises diethyl fumarate
14. The process of claim 1 , wherein select cross-linked regions of the layers of the construct are offset to form a porous network .
15. The process of claim 1 wherein the UV laser of the stereolithography instrument is tuned to polymerize the primary polymer to a depth of 0.1 mm (100 micron), and to produce solid polymeric layers having a thickness of 0.1 mm.
16. A construct made by the following process:
(a) providing a solution comprising chains of a primary photocurable, bioerodable polymer, a primary photoinitiator for promoting photocrosslinking of the chains of the primary polymer, and a solvent, wherein the primary polymer is poly(ρropylene fumarate)(PPF);
(b) providing a stereolithography instrument comprising a primary UV laser for activating the primary photoinitiator and photocrosslinking the PPF chains;
(c) providing a three dimensional CAD image of a desired three-dimensional prosthetic implant, wherein the three-dimensional CAD image is readable by the stereolithography instrument;
(d) depositing the solution in successive layers on a build platen in the stereolithography instrument; and
(e) photocrosslinking at least a portion of the PPF chains in each of the successive layers according to corresponding cross-sectional patterns derived from the three dimensional CAD image wherein the construct has a shape and size corresponding to the desired three dimensional prosthetic implant, wherein the construct comprises solid regions comprising photocrosslinked PPF chains; and wherein the construct has a network of interconnecting pores and channels corresponding to a network of interconnecting pores and channels designed into the three CAD image, wherein one or more of the channels extend from a location inside the construct to a predetermined location on the exterior surface of the construct, and wherein the one or more channels are for promoting migration of vascular and bone progenitor cells into the interior of the construct.
17. The construct of claim 16 wherein the solution further comprises bioactive molecules and the construct further comprises bioactive molecules.
18. The construct of claim 16 wherein the diameter of the pores and channels is from about 100 microns to about 1000 microns.
19. A construct made by the process of claim 1 In certain embodiments, the prosthetic implant is a composite prosthetic implant wherein a portion or all of the solid regions of the prosthetic implant comprise a photcrosslinked primary polymer and a photocrosslinked secondary polymer. In other embodiments, the prosthetic implant is a composite prosthetic implant wherein a first group of solid regions in the prosthetic implant comprise the photocrosslinked primary polymer and a second group of solid regions in the prosthetic implant comprise a photocrosslinked secondary polymer. The prosthetic implant may also comprise bioactive molecules.
19. A composite polymeric construct made by a process comprising the steps of:
(a) providing a solution comprising chains of a primary photocurable, bioerodable polymer and a secondary photocurable polymer, a primary photoinitiator for promoting photocrosslinking of the chains of the primary polymer, a secondary photoinitiator for promoting photocrosslinking of the chains of the secondary polymer, and a solvent, wherein the primary polymer is poly(propylene fumarate)(PPF);
(b) providing a stereolithography instrument comprising a primary UV laser for activating the primary photoinitiator and photocrosslinking the PPF chains, and a secondary UV laser for activating the secondary photoinitiator and photocrosslinking chains of the secondary polymer;
(c) providing a three dimensional CAD image of a desired three-dimensional prosthetic implant, wherein the three-dimensional CAD image is readable by the stereolithography instrument;
(d) depositing the solution in successive layers on a build platen in the stereolithography instrument; and
(e) photocrosslinking PPF chains and chains of the secondary polymer in each of the successive layers according to corresponding cross-sectional patterns derived from the three dimensional CAD image; wherein the composite polymeric construct has a shape and size corresponding to the three-dimensional CAD image, wherein the composite polymeric construct comprises solid regions comprising photocrosslinked PPF chains; wherein the composite polymeric construct comprises solid regions comprising photocrosslinked chains of the secondary polymer; and wherein the prosthetic implant has a network of interconnecting pores and channels leading from the exterior surface to an interior location in the prosthetic implant.
20. The composite polymeric construct of claim 19 wherein the solution further comprises bioactive molecules, and the composite polymeric construct further comprises bioactive molecules.
PCT/US2002/012283 2001-04-19 2002-04-19 Fabrication of a polymeric prosthetic implant WO2002085246A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002305201A AU2002305201A1 (en) 2001-04-19 2002-04-19 Fabrication of a polymeric prosthetic implant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28480301P 2001-04-19 2001-04-19
US60/284,803 2001-04-19

Publications (2)

Publication Number Publication Date
WO2002085246A2 true WO2002085246A2 (en) 2002-10-31
WO2002085246A3 WO2002085246A3 (en) 2002-12-19

Family

ID=23091583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/012283 WO2002085246A2 (en) 2001-04-19 2002-04-19 Fabrication of a polymeric prosthetic implant

Country Status (3)

Country Link
US (1) US6849223B2 (en)
AU (1) AU2002305201A1 (en)
WO (1) WO2002085246A2 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1409566A2 (en) * 2001-06-28 2004-04-21 Wm. MARSH RICE UNIVERSITY Photocrosslinking of diethyl fumarate/poly(propylene fumarate) biomaterials
WO2006091097A2 (en) * 2005-01-14 2006-08-31 Cam Implants B.V. Two-dimensional and three-dimensional structures with a pattern identical to that of e.g. cancellous bone
US7419630B2 (en) 2005-04-22 2008-09-02 Sandia Corporation Methods and systems for rapid prototyping of high density circuits
US7556490B2 (en) 2004-07-30 2009-07-07 Board Of Regents, The University Of Texas System Multi-material stereolithography
US7658603B2 (en) 2005-03-31 2010-02-09 Board Of Regents, The University Of Texas System Methods and systems for integrating fluid dispensing technology with stereolithography
US7780897B2 (en) 2005-04-22 2010-08-24 Board Of Regents, The University Of Texas System Hydrogel constructs using stereolithography
WO2011141152A3 (en) * 2010-05-12 2012-01-05 Eos Gmbh Electro Optical Systems Building-space changing device and an apparatus for producing a three-dimensional object with a building-space changing device
EP2463081A1 (en) * 2010-12-09 2012-06-13 3M Innovative Properties Co. A system comprising a rapid prototyping device and a material cartridge, a cartridge, and a method of using the system
ITMI20131383A1 (en) * 2013-08-12 2015-02-13 Francesco Matteo Davolio MEASURED PREFORMATION METHOD OF PLATES AND MESH FOR OSTEOSYNTHESIS
AU2013202075B2 (en) * 2012-04-06 2015-08-27 Howmedica Osteonics Corp Surface modified unit cell lattice structures for optimized secure freeform fabrication
US9135374B2 (en) 2012-04-06 2015-09-15 Howmedica Osteonics Corp. Surface modified unit cell lattice structures for optimized secure freeform fabrication
WO2016081587A1 (en) * 2014-11-18 2016-05-26 The University Of Akron Well-defined degradable poly(propylene fumarate) polymers and scalable methods for the synthesis thereof
US9456901B2 (en) 2004-12-30 2016-10-04 Howmedica Osteonics Corp. Laser-produced porous structure
EP3003722A4 (en) * 2013-05-31 2017-01-18 Hewlett-Packard Development Company, L.P. Modifying a base layer of an object
US9668863B2 (en) 2009-08-19 2017-06-06 Smith & Nephew, Inc. Porous implant structures
WO2018204611A1 (en) * 2017-05-03 2018-11-08 The University Of Akron Post-3d printing functionalization of polymer scaffolds for enhanced bioactivity
US10398559B2 (en) 2005-12-06 2019-09-03 Howmedica Osteonics Corp. Laser-produced porous surface
CN110366434A (en) * 2017-02-02 2019-10-22 阿克伦大学 Functionalized poly (fumaric acid acrylic ester) polymer prepared using Mg catalyst by ring-opening polymerisation
US11155073B2 (en) 2002-11-08 2021-10-26 Howmedica Osteonics Corp. Laser-produced porous surface
US11298747B2 (en) 2017-05-18 2022-04-12 Howmedica Osteonics Corp. High fatigue strength porous structure
WO2024033692A1 (en) * 2022-08-12 2024-02-15 Eskandamejad Vida A method for customized synthetic block graft with 3-dimensional stereolithography

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005505352A (en) * 2001-10-11 2005-02-24 シュトラウマン・ホールディング・アクチェンゲゼルシャフト Osteophilic implant
US8175683B2 (en) * 2003-12-30 2012-05-08 Depuy Products, Inc. System and method of designing and manufacturing customized instrumentation for accurate implantation of prosthesis by utilizing computed tomography data
US8241905B2 (en) 2004-02-24 2012-08-14 The Curators Of The University Of Missouri Self-assembling cell aggregates and methods of making engineered tissue using the same
US8394142B2 (en) * 2005-06-13 2013-03-12 Synthes Usa, Llc Customizing an intervertebral implant
US7930054B2 (en) * 2006-03-27 2011-04-19 The Boeing Company Method and system for toolpath generation
WO2008101134A1 (en) * 2007-02-14 2008-08-21 Brigham And Women's Hospital, Inc. Crosslinked polymers and methods of making the same
US8327519B2 (en) * 2008-04-14 2012-12-11 Linares Medical Devices, Llc Multi-level machine for duplicating a sectioned and scanned bone end and for producing a fitting implant replacement
FR2932674B1 (en) 2008-06-20 2011-11-18 Tornier Sa METHOD FOR MODELING A GLENOIDAL SURFACE OF AN OMOPLATE, DEVICE FOR IMPLANTING A GLENOIDAL COMPONENT OF A SHOULDER PROSTHESIS, AND METHOD FOR MANUFACTURING SUCH COMPOUND
WO2010008905A2 (en) 2008-06-24 2010-01-21 The Curators Of The University Of Missouri Self-assembling multicellular bodies and methods of producing a three-dimensional biological structure using the same
US7955875B2 (en) * 2008-09-26 2011-06-07 Cree, Inc. Forming light emitting devices including custom wavelength conversion structures
WO2010102059A1 (en) * 2009-03-03 2010-09-10 The Trustees Of Columbia University In The City Of New York Methods, devices, and systems for bone tissue engineering using a bioreactor
KR101879438B1 (en) * 2010-08-20 2018-08-17 케이스 웨스턴 리저브 유니버시티 Continuous digital light processing additive manufacturing of implants
US11865785B2 (en) * 2010-08-20 2024-01-09 H. David Dean Continuous digital light processing additive manufacturing of implants
CA2812766C (en) 2010-10-21 2021-06-29 Organovo, Inc. Devices, systems, and methods for the fabrication of tissue
US9386525B2 (en) 2012-04-20 2016-07-05 Acer Incorporated Method of handling transferring from energy-consuming mode to energy-saving mode and related communication device
US9499779B2 (en) * 2012-04-20 2016-11-22 Organovo, Inc. Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking
AU2013267381B2 (en) * 2012-05-30 2016-03-31 New York University Tissue repair devices and scaffolds
DE102012011418A1 (en) 2012-06-08 2013-12-12 Universität Rostock Stereolithography system
MX2015006002A (en) * 2012-11-14 2016-02-05 Orthopaedic Innovation Ct Inc Antimicrobial articles produced by additive manufacturing.
US9442105B2 (en) 2013-03-15 2016-09-13 Organovo, Inc. Engineered liver tissues, arrays thereof, and methods of making the same
WO2014197790A1 (en) 2013-06-06 2014-12-11 University Of Maryland, College Park Compositions and methods for making biodegradable structures
KR20160036619A (en) 2013-07-31 2016-04-04 오가노보, 인크. Automated devices, systems, and methods for the fabrication of tissue
DE102013021961A1 (en) 2013-12-20 2015-07-09 Universität Rostock Stereolithography system
CA3177480A1 (en) 2014-04-04 2015-10-08 Organovo, Inc. Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model
CN104014790A (en) * 2014-04-23 2014-09-03 张远明 3D ink-jet printer for printing electronic circuit board through ultrasonic atomization nanometer suspending liquid
AT516324B1 (en) * 2014-07-22 2016-06-15 Way To Production Gmbh System for forming a dimensionally stable object by selective, area-wise solidification of a non-dimensionally stable mass
US9481868B2 (en) 2014-10-06 2016-11-01 Organovo, Inc. Engineered renal tissues, arrays thereof, and methods of making the same
WO2016073782A1 (en) 2014-11-05 2016-05-12 Organovo, Inc. Engineered three-dimensional skin tissues, arrays thereof, and methods of making the same
US10279078B2 (en) * 2014-12-31 2019-05-07 Bacterin International, Inc. Crosslinkable 3D printed biomaterial-based implants and methods of manufacture thereof
AU2016371425B2 (en) 2015-12-16 2021-09-02 Howmedica Osteonics Corp. Patient specific instruments and methods for joint prosthesis
CN105425388B (en) * 2015-12-25 2017-12-19 深圳市国华光电科技有限公司 A kind of preparation method of electric moistening display divider
US10668708B2 (en) 2016-09-27 2020-06-02 Lawrence Livermore National Security, Llc Optically enhanced patternable photosensitivity via oxygen excitation
US10940638B2 (en) * 2017-01-24 2021-03-09 Continuous Composites Inc. Additive manufacturing system having finish-follower
EP3579793B1 (en) 2017-02-13 2021-03-31 Össur Iceland EHF Orthopedic device
EP3607046A4 (en) 2017-04-07 2020-05-27 Epibone, Inc. System and method for seeding and culturing
US10828833B2 (en) * 2017-06-02 2020-11-10 3D Systems, Inc. Three dimensional printing system with improved support fixture
WO2019014281A1 (en) 2017-07-11 2019-01-17 Tornier, Inc. Patient specific humeral cutting guides
US11166733B2 (en) 2017-07-11 2021-11-09 Howmedica Osteonics Corp. Guides and instruments for improving accuracy of glenoid implant placement
US10926467B2 (en) * 2019-04-15 2021-02-23 Zhejiang Xunshi Technology Co., Ltd 3D printer with multiple light sources and its controlling method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US6261493B1 (en) * 1997-03-20 2001-07-17 Therics, Inc. Fabrication of tissue products with additives by casting or molding using a mold formed by solid free-form methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996010A (en) * 1988-04-18 1991-02-26 3D Systems, Inc. Methods and apparatus for production of three-dimensional objects by stereolithography
GB9717433D0 (en) * 1997-08-19 1997-10-22 Univ Nottingham Biodegradable composites
EP1079869B1 (en) * 1998-04-10 2005-03-23 Wm. MARSH RICE UNIVERSITY Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261493B1 (en) * 1997-03-20 2001-07-17 Therics, Inc. Fabrication of tissue products with additives by casting or molding using a mold formed by solid free-form methods
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1409566A2 (en) * 2001-06-28 2004-04-21 Wm. MARSH RICE UNIVERSITY Photocrosslinking of diethyl fumarate/poly(propylene fumarate) biomaterials
EP1409566A4 (en) * 2001-06-28 2005-02-16 Univ Wm Marsh Rice Photocrosslinking of diethyl fumarate/poly(propylene fumarate) biomaterials
US11510783B2 (en) 2002-11-08 2022-11-29 Howmedica Osteonics Corp. Laser-produced porous surface
US11186077B2 (en) 2002-11-08 2021-11-30 Howmedica Osteonics Corp. Laser-produced porous surface
US11155073B2 (en) 2002-11-08 2021-10-26 Howmedica Osteonics Corp. Laser-produced porous surface
US7556490B2 (en) 2004-07-30 2009-07-07 Board Of Regents, The University Of Texas System Multi-material stereolithography
US11660195B2 (en) 2004-12-30 2023-05-30 Howmedica Osteonics Corp. Laser-produced porous structure
US9456901B2 (en) 2004-12-30 2016-10-04 Howmedica Osteonics Corp. Laser-produced porous structure
WO2006091097A2 (en) * 2005-01-14 2006-08-31 Cam Implants B.V. Two-dimensional and three-dimensional structures with a pattern identical to that of e.g. cancellous bone
WO2006091097A3 (en) * 2005-01-14 2006-11-16 Cam Implants Bv Two-dimensional and three-dimensional structures with a pattern identical to that of e.g. cancellous bone
US8252223B2 (en) 2005-03-31 2012-08-28 Board Of Regents, The University Of Texas System Methods and systems for integrating fluid dispensing technology with stereolithography
US7658603B2 (en) 2005-03-31 2010-02-09 Board Of Regents, The University Of Texas System Methods and systems for integrating fluid dispensing technology with stereolithography
US8197743B2 (en) 2005-04-22 2012-06-12 Keck Graduate Institute Hydrogel constructs using stereolithography
US7419630B2 (en) 2005-04-22 2008-09-02 Sandia Corporation Methods and systems for rapid prototyping of high density circuits
US7780897B2 (en) 2005-04-22 2010-08-24 Board Of Regents, The University Of Texas System Hydrogel constructs using stereolithography
US11918474B2 (en) 2005-12-06 2024-03-05 The University Of Liverpool Laser-produced porous surface
US10716673B2 (en) 2005-12-06 2020-07-21 Howmedica Osteonics Corp. Laser-produced porous surface
US10398559B2 (en) 2005-12-06 2019-09-03 Howmedica Osteonics Corp. Laser-produced porous surface
US10588749B2 (en) 2009-08-19 2020-03-17 Smith & Nephew, Inc. Porous implant structures
US9668863B2 (en) 2009-08-19 2017-06-06 Smith & Nephew, Inc. Porous implant structures
US11793645B2 (en) 2009-08-19 2023-10-24 Smith & Nephew, Inc. Porous implant structures
US11529235B2 (en) 2009-08-19 2022-12-20 Smith & Nephew, Inc. Porous implant structures
US10945847B2 (en) 2009-08-19 2021-03-16 Smith & Nephew, Inc. Porous implant structures
US8845319B2 (en) 2010-05-12 2014-09-30 Eos Gmbh Electro Optical Systems Means for modifying a building space and device for manufacturing a three-dimensional object having means for modifying a building space
WO2011141152A3 (en) * 2010-05-12 2012-01-05 Eos Gmbh Electro Optical Systems Building-space changing device and an apparatus for producing a three-dimensional object with a building-space changing device
WO2012078533A1 (en) * 2010-12-09 2012-06-14 3M Innovative Properties Company A system comprising a rapid prototyping device and a material cartridge, a cartridge, and a method of using the system
US9204945B2 (en) 2010-12-09 2015-12-08 3M Innovative Properties Company System comprising a rapid prototyping device and a material cartridge, a cartridge, and a method of using the system
EP2463081A1 (en) * 2010-12-09 2012-06-13 3M Innovative Properties Co. A system comprising a rapid prototyping device and a material cartridge, a cartridge, and a method of using the system
US9180010B2 (en) 2012-04-06 2015-11-10 Howmedica Osteonics Corp. Surface modified unit cell lattice structures for optimized secure freeform fabrication
AU2013202075B2 (en) * 2012-04-06 2015-08-27 Howmedica Osteonics Corp Surface modified unit cell lattice structures for optimized secure freeform fabrication
US10614176B2 (en) 2012-04-06 2020-04-07 Howmedica Osteonics Corp. Surface modified unit cell lattice structures for optimized secure freeform fabrication
US9135374B2 (en) 2012-04-06 2015-09-15 Howmedica Osteonics Corp. Surface modified unit cell lattice structures for optimized secure freeform fabrication
US11759323B2 (en) 2012-04-06 2023-09-19 Howmedica Osteonics Corp. Surface modified unit cell lattice structures for optimized secure freeform fabrication
US10850450B2 (en) 2013-05-31 2020-12-01 Hewlett-Packard Development Company, L.P. Modifying a base layer of an object
EP3003722A4 (en) * 2013-05-31 2017-01-18 Hewlett-Packard Development Company, L.P. Modifying a base layer of an object
ITMI20131383A1 (en) * 2013-08-12 2015-02-13 Francesco Matteo Davolio MEASURED PREFORMATION METHOD OF PLATES AND MESH FOR OSTEOSYNTHESIS
JP2018500450A (en) * 2014-11-18 2018-01-11 アクロン大学 Well-defined degradable poly (propylene fumarate) polymers and extensible methods for their synthesis
WO2016081587A1 (en) * 2014-11-18 2016-05-26 The University Of Akron Well-defined degradable poly(propylene fumarate) polymers and scalable methods for the synthesis thereof
AU2015349988B2 (en) * 2014-11-18 2019-08-01 The Ohio State University Well-defined degradable poly(propylene fumarate) polymers and scalable methods for the synthesis thereof
US10465044B2 (en) 2014-11-18 2019-11-05 The University Of Akron Well-defined degradable poly(propylene fumarate) polymers and scalable methods for the synthesis thereof
US11499008B2 (en) 2017-02-02 2022-11-15 University Of Akron Functionalized poly (propylene fumarate) polymers made by ring opening polymerization using magnesium catalysts
CN110366434A (en) * 2017-02-02 2019-10-22 阿克伦大学 Functionalized poly (fumaric acid acrylic ester) polymer prepared using Mg catalyst by ring-opening polymerisation
EP3576801A4 (en) * 2017-02-02 2020-12-16 The University of Akron Functionalized poly(propylene fumarate) polymers made by ring opening polymerization using magnesium catalysts
IL268207B1 (en) * 2017-02-02 2024-04-01 Univ Akron Functionalized poly(propylene fumarate) polymers made by ring opening polymerization using magnesium catalysts
WO2018204611A1 (en) * 2017-05-03 2018-11-08 The University Of Akron Post-3d printing functionalization of polymer scaffolds for enhanced bioactivity
US11931478B2 (en) 2017-05-03 2024-03-19 The University Of Akron Post-3D printing functionalization of polymer scaffolds for enhanced bioactivity
US11298747B2 (en) 2017-05-18 2022-04-12 Howmedica Osteonics Corp. High fatigue strength porous structure
US11684478B2 (en) 2017-05-18 2023-06-27 Howmedica Osteonics Corp. High fatigue strength porous structure
WO2024033692A1 (en) * 2022-08-12 2024-02-15 Eskandamejad Vida A method for customized synthetic block graft with 3-dimensional stereolithography

Also Published As

Publication number Publication date
WO2002085246A3 (en) 2002-12-19
US20020171178A1 (en) 2002-11-21
AU2002305201A1 (en) 2002-11-05
US6849223B2 (en) 2005-02-01

Similar Documents

Publication Publication Date Title
US6849223B2 (en) Fabrication of a polymeric prosthetic implant
Melchels et al. A review on stereolithography and its applications in biomedical engineering
JP6027533B2 (en) Additional manufacturing of implants by continuous digital light processing
Arcaute et al. Stereolithography of three-dimensional bioactive poly (ethylene glycol) constructs with encapsulated cells
Cooke et al. Use of stereolithography to manufacture critical‐sized 3D biodegradable scaffolds for bone ingrowth
JP6362614B2 (en) Absorbents and biocompatible reflective dyes for high precision medical implants
Bandyopadhyay et al. Three-dimensional printing of biomaterials and soft materials
Husár et al. Photopolymerization-based additive manufacturing for the development of 3D porous scaffolds
Hart et al. 3D and 4D printing of biomaterials and biocomposites, bioinspired composites, and related transformers
Oliaei et al. 6. Stereolithography and its applications
Ronca et al. Polymer based scaffolds for tissue regeneration by stereolithography
US20190210355A1 (en) Absorbant and reflecting biocompatible dyes for highly accurate medical implants
Cooke Novel stereolithographic manufacture of biodegradable bone tissue scaffolds
Enbergs et al. 3D Printing of Bone Substitutes Based on Vat Photopolymerization Processes: A Systematic Review
Baino et al. Additive manufacturing of bioceramic scaffolds for bone tissue regeneration with emphasis on stereolithographic processing
US20240100777A1 (en) Continuous digital light processing additive manufacturing of implants
Dean et al. Stereolithographic rendering of low molecular weight polymer scaffolds for bone tissue engineering
Dean et al. The calibration of continuous Digital Light Processing (cDLP) for the highly accurate additive manufacturing of tissue engineered bone scaffolds
Ashok et al. 3D PRINTING OF HYDROXYAPATITE BASED COMPOSITES FOR BONE ENGINEERING
CN116194134A (en) Collagen with selective properties, collagen product containing the same and method for producing the same
Cantu Stereolithography of poly (ethylene glycol) hydrogels with application in tissue engineering as peripheral nerve regeneration scaffolds
Young Fundamentals of crosslinking photopolymerizations and applications to biomedical systems
CN117580702A (en) Method for producing printable objects
KR20090097402A (en) Fabrication method of drug deliverable property scaffold for tissue regeneration
Fisher The development of a photocrosslinked biomaterial for bone tissue engineering applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP